{"prompt": "['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.11.', 'Appendix 11 Protocol Amendment History', 'Table 1', 'Schedule of activities', 'Original text:', 'FU', 'Up to', '28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'EW', 'Visit1a', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', 'days', 'post', 'last', 'dose', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'up to', '0/', '2/', '4/', '8/', '12/', '16', '20 /', '24', '32', '40/', '52 /', '-7 days', 'D1', 'D14', 'D28', 'D56', 'D84', 'D112', 'D140', 'D168', 'D224', 'D280', 'D364', 'Assessment', '+3d', '+3d', '+3d', '3d', '3d', '+3d', '3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'window', 'Urine or', 'serum', 'X', 'Pregnancy', 'testg', 'HIV,', 'Hepatitis B', 'and C', 'screeninge', 'AE review', 'SAE review', 'Revised text:', 'FU', 'Up to', '28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'EW', 'Visit1a', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', 'days', 'post', 'last', 'dose', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'up to', '0/', '2/', '4/', '8/', '12/', '16/', '20/', '24', '32', '40/', '52/', '-28 days', 'D1', 'D14', 'D28', 'D56', 'D84', 'D112', 'D140', 'D168', 'D224', 'D280', 'D364', 'Assessment', '+3d', '+3d', '+3d', '+3d', '3d', '3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'window', 'HIV,', 'Hepatitis B', 'X', 'and C', 'screeninge', 'AE review', 'SAE review', '84']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Section 5.1', 'Overall Design', 'Original text:', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days - -7 to', '1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', 'Figure 1', 'Study Schematic', '52 weeks', 'Placebo (n=50)', '7 days', 'Follow-up\u00b2', 'Screening\u00b9', 'R', 'Danirixin, 35mg', '(n=50)', '1 If changes to medication are required, consent must be signed prior to any changes being made and may', 'occur prior to the Screening Visit', '2', 'Follow-up visit to occur within 28days of last dose of study medication', 'Amended text:', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days -28', 'to 1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', '85']\n\n###\n\n", "completion": "END"}